Pemazyre (pemigatinib)

News alerts, weekly reports and conference planners

Company:

Incyte, Innovent Biologics, Knight Therap, Specialised Therap

Drug class:

FGFR inhibitor

Related drugs:

FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 translocation	Cholangiocarcinoma	FGFR2 translocation	Cholangiocarcinoma	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR mutation	Urothelial Cancer	FGFR mutation	Urothelial Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR mutation	Pancreatic Cancer	FGFR mutation	Pancreatic Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR fusion	Pancreatic Cancer	FGFR fusion	Pancreatic Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR3 fusion	Urothelial Cancer	FGFR3 fusion	Urothelial Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGF10 amplification	Urothelial Cancer	FGF10 amplification	Urothelial Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR2 C382R	Cholangiocarcinoma	FGFR2 C382R	Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR2 F276C	Cholangiocarcinoma	FGFR2 F276C	Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR1 A354V	Esophageal Cancer	FGFR1 A354V	Esophageal Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR1 rearrangement	Myelodysplastic Syndrome	FGFR1 rearrangement	Myelodysplastic Syndrome	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Cholangiocarcinoma	FGFR mutation	Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Non Small Cell Lung Cancer	FGFR mutation	Non Small Cell Lung Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Astrocytoma	FGFR mutation	Astrocytoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Uterine Cancer	FGFR mutation	Uterine Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Gallbladder Cancer	FGFR mutation	Gallbladder Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Head and Neck Cancer	FGFR mutation	Head and Neck Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Cholangiocarcinoma	FGFR fusion	Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Urothelial Cancer	FGFR fusion	Urothelial Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Non Small Cell Lung Cancer	FGFR fusion	Non Small Cell Lung Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Astrocytoma	FGFR fusion	Astrocytoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Uterine Cancer	FGFR fusion	Uterine Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Gallbladder Cancer	FGFR fusion	Gallbladder Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Head and Neck Cancer	FGFR fusion	Head and Neck Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR3 rearrangement	Urothelial Cancer	FGFR3 rearrangement	Urothelial Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR1 mutation	Esophageal Cancer	FGFR1 mutation	Esophageal Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR2-CLIP1 fusion	Cholangiocarcinoma	FGFR2-CLIP1 fusion	Cholangiocarcinoma	pemigatinib Resistant: C4 – Case Studies pemigatinib Resistant : C4	pemigatinib Resistant: C4 – Case Studies pemigatinib Resistant : C4
FRS2 amplification	Cholangiocarcinoma	FRS2 amplification	Cholangiocarcinoma	pemigatinib Sensitive: C4 – Case Studies pemigatinib Sensitive : C4	pemigatinib Sensitive: C4 – Case Studies pemigatinib Sensitive : C4
FGFR1 rearrangement + Chr t(8;13)	Lymphoma	FGFR1 rearrangement + Chr t(8;13)	Lymphoma	pemigatinib Sensitive: C4 – Case Studies pemigatinib Sensitive : C4	pemigatinib Sensitive: C4 – Case Studies pemigatinib Sensitive : C4

Pemazyre (pemigatinib)

Associations
(41)

Associations
(41)

Pemazyre (pemigatinib)

Associations(41)

Associations(41)

Associations
(41)

Associations
(41)